UPDATE: Jefferies Initiates Coverage on Rollins at Buy on Recurring Revenues
In a report published on Wednesday, Jefferies analyst Dan Dolev initiated coverage on Rollins (NYSE: ROL) with a Buy rating and a price target of $28.
In the report, Jefferies stated, "Near term, rising healthcare costs may boost roll-ups. Most (50-90%) bed-bug clients are incremental, which can boost cross-selling. Longer term, we see a ~$30bn global opportunity and 200-500 margin upside."
Rollins closed on Wednesday at $24.33.
Latest Ratings for ROL
Date | Firm | Action | From | To |
---|---|---|---|---|
Oct 2020 | Stifel | Maintains | Hold | |
Jul 2020 | RBC Capital | Maintains | Sector Perform | |
Feb 2020 | Buckingham | Maintains | Neutral |
View More Analyst Ratings for ROL
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Dan Dolev Jefferies NYSE RollinsAnalyst Color Initiation Analyst Ratings